Crossmark Global Holdings Inc. Buys 6,214 Shares of Zoetis Inc. (NYSE:ZTS)

Crossmark Global Holdings Inc. increased its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 16.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,150 shares of the company's stock after acquiring an additional 6,214 shares during the period. Crossmark Global Holdings Inc.'s holdings in Zoetis were worth $7,105,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. HUB Investment Partners LLC raised its position in Zoetis by 4.7% during the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after acquiring an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC raised its position in shares of Zoetis by 18.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after purchasing an additional 64 shares during the period. Ironwood Investment Management LLC raised its position in shares of Zoetis by 0.8% in the fourth quarter. Ironwood Investment Management LLC now owns 8,354 shares of the company's stock valued at $1,361,000 after purchasing an additional 68 shares during the period. Legacy Financial Advisors Inc. raised its position in shares of Zoetis by 5.8% in the fourth quarter. Legacy Financial Advisors Inc. now owns 1,282 shares of the company's stock valued at $209,000 after purchasing an additional 70 shares during the period. Finally, Broadway Wealth Solutions Inc. raised its position in shares of Zoetis by 4.4% in the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock valued at $287,000 after purchasing an additional 73 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ZTS shares. UBS Group dropped their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Piper Sandler increased their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. Finally, Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $212.13.

Zoetis Price Performance

Zoetis stock traded up $0.67 during trading hours on Tuesday, reaching $157.72. 2,885,127 shares of the stock were exchanged, compared to its average volume of 2,575,010. The company has a market cap of $70.22 billion, a P/E ratio of 28.32, a price-to-earnings-growth ratio of 2.64 and a beta of 0.91. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The stock has a 50 day moving average of $161.23 and a two-hundred day moving average of $162.02.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The business's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.38 earnings per share. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. Zoetis's dividend payout ratio (DPR) is currently 35.91%.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.16% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.